Novo Nordisk Inc patents expiration
1. Levemir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6869930 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
| US6011007 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
| US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-117) | May 18, 2015 |
| M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
LEVEMIR family patents
2. Levemir Flexpen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6869930 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
| US6011007 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
| US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
| USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-117) | May 18, 2015 |
| M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXPEN family patents
3. Levemir Flextouch patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
| US9486588 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8672898 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US6899699 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(25 days from now) | |
| US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 5 months from now) | |
| US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
| USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
| US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
| US9687611 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US9457154 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
| US9132239 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-117) | May 18, 2015 |
| M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXTOUCH family patents
4. Levemir Innolet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6011007 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
| US6869930 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
| US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-117) | May 18, 2015 |
| M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
LEVEMIR INNOLET family patents
5. Levemir Penfill patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6869930 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
| US6011007 | NOVO NORDISK INC | Acylated insulin |
Feb, 2014
(10 years ago) | |
| US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-117) | May 18, 2015 |
| M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
LEVEMIR PENFILL family patents
6. Norditropin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5633352 | NOVO NORDISK INC | Biosynthetic human growth hormone |
May, 2014
(9 years ago) | |
| US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN ingredient
Market Authorisation Date: 23 January, 2015
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE;INJECTION
NORDITROPIN family patents
7. Norditropin Flexpro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| US8841252 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2017
(6 years ago) | |
| US6716198 | NOVO NORDISK INC | Injection device |
Jun, 2021
(2 years ago) | |
| US9486588 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US6899699 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8672898 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(25 days from now) | |
| US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 5 months from now) | |
| US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
| US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
| US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
| US9687611 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US9457154 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
| US9132239 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN ingredient
Market Authorisation Date: 23 January, 2015
Treatment: Treatment of disorders responsive to growth hormone
Dosage: INJECTABLE;INJECTION
NORDITROPIN FLEXPRO family patents
8. Norditropin Nordiflex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(8 years ago) | |
| US8841252 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2017
(6 years ago) | |
| US6235004 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN ingredient
Market Authorisation Date: 23 January, 2015
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE;INJECTION
NORDITROPIN NORDIFLEX family patents
9. Novolog patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG family patents
10. Novolog Flexpen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
| USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
|
US6004297 (Pediatric) | NOVO NORDISK INC | Injection syringe |
Jul, 2019
(4 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
|
USRE41956 (Pediatric) | NOVO NORDISK INC | Dose setting limiter |
Jul, 2021
(2 years ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(25 days from now) | |
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG FLEXPEN family patents
11. Novolog Flextouch patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
| US9486588 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US6899699 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8672898 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(25 days from now) | |
| US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 5 months from now) | |
| US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
| US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
| US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
| US9687611 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US9457154 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
| US9132239 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG FLEXTOUCH family patents
12. Novolog Innolet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
|
USRE41956 (Pediatric) | NOVO NORDISK INC | Dose setting limiter |
Jul, 2021
(2 years ago) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG INNOLET family patents
13. Novolog Mix 50/50 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5547930 | NOVO NORDISK INC | AspB28 insulin crystals |
Sep, 2013
(10 years ago) | |
| US5840680 | NOVO NORDISK INC | ASPB28 insulin crystals |
Sep, 2013
(10 years ago) | |
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5834422 | NOVO NORDISK INC | AspB28 insulin compositions |
Sep, 2013
(10 years ago) | |
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
Market Authorisation Date: 26 August, 2008
Treatment: Method of treating a patient suffering from diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG MIX 50/50 family patents
14. Novolog Mix 70/30 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5547930 | NOVO NORDISK INC | AspB28 insulin crystals |
Sep, 2013
(10 years ago) | |
| US5840680 | NOVO NORDISK INC | ASPB28 insulin crystals |
Sep, 2013
(10 years ago) | |
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5834422 | NOVO NORDISK INC | AspB28 insulin compositions |
Sep, 2013
(10 years ago) | |
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
Market Authorisation Date: 01 November, 2001
Treatment: Method of treating a patient suffering from diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG MIX 70/30 family patents
15. Novolog Mix 70/30 Flexpen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5547930 | NOVO NORDISK INC | AspB28 insulin crystals |
Sep, 2013
(10 years ago) | |
| US5840680 | NOVO NORDISK INC | ASPB28 insulin crystals |
Sep, 2013
(10 years ago) | |
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5834422 | NOVO NORDISK INC | AspB28 insulin compositions |
Sep, 2013
(10 years ago) | |
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
| USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(25 days from now) | |
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
Market Authorisation Date: 01 November, 2001
Treatment: Method of treating a patient suffering from diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG MIX 70/30 FLEXPEN family patents
16. Novolog Mix 70/30 Penfill patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5547930 | NOVO NORDISK INC | AspB28 insulin crystals |
Sep, 2013
(10 years ago) | |
| US5840680 | NOVO NORDISK INC | ASPB28 insulin crystals |
Sep, 2013
(10 years ago) | |
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5834422 | NOVO NORDISK INC | AspB28 insulin compositions |
Sep, 2013
(10 years ago) | |
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
Market Authorisation Date: 01 November, 2001
Treatment: Method of treating a patient suffering from diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG MIX 70/30 PENFILL family patents
17. Novolog Penfill patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5626566 | NOVO NORDISK INC | Large dose pen |
May, 2014
(9 years ago) | |
|
US5626566 (Pediatric) | NOVO NORDISK INC | Large dose pen |
Nov, 2014
(9 years ago) | |
| US5693027 | NOVO NORDISK INC | Adaptor top |
Dec, 2014
(9 years ago) | |
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
|
US5693027 (Pediatric) | NOVO NORDISK INC | Adaptor top |
Jun, 2015
(8 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(25 days from now) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG PENFILL family patents
18. Prandimet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6677358 | NOVO NORDISK INC | NIDDM regimen |
Jun, 2018
(5 years ago) | |
Drugs and Companies using METFORMIN HYDROCHLORIDE; REPAGLINIDE ingredient
Market Authorisation Date: 23 June, 2008
Treatment: Use of repaglinide in combination with metformin to lower blood glucose
Dosage: TABLET;ORAL
PRANDIMET family patents
19. Vagifem patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5860946 | NOVO NORDISK INC | Instrument for inserting a suppository |
Jul, 2017
(6 years ago) | |
| US7018992 | NOVO NORDISK INC | Hormone composition |
Sep, 2022
(1 year, 7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-122) | Nov 25, 2012 |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 25 November, 2009
Treatment: Treatment of atrophic vaginitis due to menopause
Dosage: TABLET;VAGINAL
VAGIFEM family patents
20. Victoza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6458924 | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Aug, 2017
(6 years ago) | |
| US7235627 | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Aug, 2017
(6 years ago) | |
| US6268343 | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Aug, 2022
(1 year, 8 months ago) | |
| US8114833 | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
|
USRE41956 (Pediatric) | NOVO NORDISK INC | Dose setting limiter |
Jul, 2021
(2 years ago) | |
| US8846618 | NOVO NORDISK INC | Stable formulation of modified GLP-1 |
Jun, 2022
(1 year, 10 months ago) | |
|
US8846618 (Pediatric) | NOVO NORDISK INC | Stable formulation of modified GLP-1 |
Dec, 2022
(1 year, 4 months ago) | |
|
US6268343 (Pediatric) | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Feb, 2023
(1 year, 2 months ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(9 months ago) | |
|
US8579869 (Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(3 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(25 days from now) | |
|
US7762994 (Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(6 months from now) | |
|
US8114833 (Pediatric) | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(1 year, 9 months from now) | |
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
|
US9265893 (Pediatric) | NOVO NORDISK INC | Injection button |
Mar, 2033
(8 years from now) | |
| US9968659 | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jan, 2037
(12 years from now) | |
|
US9968659 (Pediatric) | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jul, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-176) | Apr 22, 2019 |
| New Patient Population(NPP) | Jun 17, 2022 |
| New Indication(I-750) | Aug 25, 2020 |
| Pediatric Exclusivity(PED) | Dec 17, 2022 |
| M(M-115) | Apr 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...
Dosage: SOLUTION;SUBCUTANEOUS
VICTOZA family patents